New hope for kids with rare Muscle-Weakening disease
NCT ID NCT06987539
Summary
This study is testing a drug called inebilizumab in children aged 2 to 18 who have generalized myasthenia gravis (gMG), a rare autoimmune disease that causes severe muscle weakness. The main goals are to understand how children's bodies process the drug and to check if it is safe and well-tolerated. It is a small, early-stage study enrolling about 15 participants at multiple locations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Neuromuscular Center
RECRUITINGAustin, Texas, 78759, United States
Conditions
Explore the condition pages connected to this study.